STOCK TITAN

Vistagen: Investors hold warrants for 1.69M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. (VTGN) is the issuer whose common stock is covered by an amended beneficial-ownership report from Biotechnology Value Fund, L.P.; BVF I GP LLC; Biotechnology Value Fund II, L.P.; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP Holdings LLC; BVF Partners L.P.; BVF Inc.; and Mark N. Lampert, a director and officer of BVF Inc.

As of September 30, 2026, the reporting persons and a Partners Managed Account held tranche 2 warrants exercisable for an aggregate 1,690,014 shares (or pre-funded warrants in lieu). The warrants are exercisable on or after October 4, 2023, at an exercise price of $8.877 per share, and expire October 4, 2028. A 9.99% beneficial-ownership blocker did not limit exercise as of September 30, 2026.

Shares underlying aggregate tranche 2 warrants 1,690,014 shares Held by the reporting persons and Partners Managed Account as of September 30, 2026
Shares beneficially owned by Biotechnology Value Fund, L.P. 870,943 shares Underlying tranche 2 warrants as of September 30, 2026
Shares beneficially owned by Biotechnology Value Fund II, L.P. 706,692 shares Underlying tranche 2 warrants as of September 30, 2026
Shares beneficially owned by Biotechnology Value Trading Fund OS LP 86,906 shares Underlying tranche 2 warrants as of September 30, 2026
Warrant exercise price $8.877 per share Tranche 2 warrants
Warrant exercise blocker 9.99% Beneficial-ownership limit after exercise, including affiliates
Shares outstanding 44,376,911 shares As of August 10, 2026; used in the reported ownership percentage calculation
Warrant expiration date October 4, 2028 Tranche 2 warrants
T2 Warrants technical
"held tranche 2 warrants (the “T2 Warrants”)"
T2 Warrants Blocker technical
"the T2 Warrants Blocker did not limit exercise"
Pre-Funded Warrants technical
"Shares (or Pre-Funded Warrants in lieu thereof)"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficially owned financial
"may be deemed to beneficially own the 1,690,014 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VTGN shares were covered by the reporting persons’ warrants?

As of September 30, 2026, the reporting persons and the Partners Managed Account held tranche 2 warrants exercisable for an aggregate of 1,690,014 shares, or pre-funded warrants in lieu.

What is the VTGN warrant ownership blocker?

The blocker prevents an exercise that would cause a holder, together with its affiliates, to beneficially own more than 9.99% of shares outstanding immediately after exercise. The reporting persons stated that it did not limit exercise as of September 30, 2026.

What percentage of VTGN did Mark N. Lampert report?

As of September 30, 2026, Mark N. Lampert may be deemed to beneficially own approximately 3.7% of VTGN’s outstanding shares. The percentage calculation uses 44,376,911 shares outstanding as of August 10, 2026, plus certain or all warrant shares as applicable. Lampert disclaims beneficial ownership of shares owned by the funds and held in the Partners Managed Account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





92840H400

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading